online pharmacy, prescription drugs online



Drugs online research references









  • Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
  • Results of treatment of irritative symptoms and urinary retention in patients 1 year after radical retropubic prostatectomy
  • Rx drugs
  • Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
  • Pharmacological characterization of unique prazosin-binding sites in human kidney.
  • High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers.
  • Studies on the functional role of alpha-adrenoceptors in the cardiac sympathetic ganglia of the dog.
  • Alpha 1-adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain.
  • Binding characteristics of naftopidil and alpha 1-adrenoceptor antagonists to prostatic alpha-adrenoceptors in benign prostatic hypertrophy.
  • The management of symptomatic benign prostatic hyperplasia with the once-daily alpha 1 blocker, terazosin.
  • Receptor subtype mediating the adrenergic sensitivity of pain behavior and ectopic discharges in neuropathic Lewis rats.
  • Hormonal and morphologic evaluation of the effects of antiandrogens on the blood supply of the rat prostate.
  • Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension
  • Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
  • Herbal and vitamin supplement use in a prostate cancer screening population.
  • Acute hemodynamic effects of terazosin in hypertensive and normotensive patients.
  • Neuropeptide Y-induced intestinal absorption: mediation by alpha 2-adrenergic receptors.
  • Postsynaptic alpha 1-blockade with terazosin does not modify insulin sensitivity in nonobese normotensive subjects.
  • Binding and functional properties of doxazosin in the human prostate adenoma and canine brain.
  • Efficacy of terazosin in the treatment of essential hypertension in blacks.
  • Reversal of left ventricular hypertrophy by terazosin in hypertensive patients.
  • Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
  • Differences in vasodilating action between ketanserin, a 5-HT2-serotonergic receptor antagonist, and terazosin, an alpha 1-adrenoceptor antagonist, in anesthetized rabbits.
  • The safety and efficacy of terazosin for the treatment of benign prostatic hyperplasia.
  • Alpha blockers and vasodilating beta blockers--influence on factors involved in the pathogenesis of vascular disease in patients with hypertension.
  • Renal hemodynamic responses to 5-hydroxytryptamine (5-HT): involvement of the 5-HT receptor subtypes in the canine kidney.
  • Role of selective alpha 1 blockers in the therapy of hypertension.
  • Long-term experience with terazosin for treatment of mild to moderate hypertension.
  • Influence of renal insufficiency on the pharmacokinetics and pharmacodynamics of terazosin.
  • Alpha-adrenoceptor blocking action of terazosin
  • Efficacy of selective alpha-1 blocker therapy in the treatment of acute urinary symptoms during radiotherapy for localized prostate cancer.
  • Effects of terazosin on the blood pressure responses to tilting in conscious animals: comparison with prazosin
  • Effects of Terazosin on Glycemic Control, Cholesterol, and Microalbuminuria in Patients with Non--Insulin-Dependent Diabetes Mellitus and Hypertension.
  • Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating.
  • Terazosin kinetics after oral and intravenous doses.
  • Effect of terazosin on urine storage and voiding in the aging male with prostatism.
  • Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy.
  • Luminal dopamine modulates canine ileal water and electrolyte transport.
  • Brain alpha 1-adrenergic neurotransmission is necessary for behavioral activation to environmental change in mice.
  • Mediation of noradrenaline-induced contractions of rat aorta by the alpha 1B-adrenoceptor subtype.
  • Effect of enalapril and terazosin on lipid metabolism in patients with essential arterial hypertension and accompanying hypercholesterolemia
  • Hemodynamic effects of terazosin in congestive heart failure.
  • The effectiveness of terazosin, an alpha1-blocker, on bladder neck obstruction as assessed by urodynamic hydraulic energy.
  • Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
  • Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog.
  • Treatment-related symptoms during the first year following transperineal 125I prostate implantation.
  • Effects of ANG-converting enzyme and alpha 1-adrenoceptor inhibition on intrarenal hemodynamics in SHR.
  • Primary care practitioners: an analysis of their perceptions of voiding dysfunction and prostate cancer.
  • Functional antagonistic activity of Rec 15/2739, a novel alpha-1 antagonist selective for the lower urinary tract, on noradrenaline-induced contraction of human prostate and mesenteric artery.
  • Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate.
  • alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.
  • A cost density analysis of benign prostatic hyperplasia.
  • Control of arteriovenous anastomoses in rabbit ear model of digital perfusion.
  • Pharmacological modulation of the cardiovascular response to hypertonic NaCl injection in the anteroventral area of the rat brain third ventricle.
  • Characterization of some novel alpha 1-adrenoceptor antagonists in human hyperplastic prostate.
  • Neodymium:YAG laser coagulation prostatectomy for patients in urinary retention.
  • Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I.
  • Terazosin blockade of nicotine-induced skin flap necrosis in the rat.
  • alpha- and beta-adrenoceptor blockade fail to prevent high sodium diet-induced left ventricular hypertrophy.
  • Two district alpha(1)-adrenoceptor subtypes in the human prostate: assessment by radioligand binding assay using 3H-prazosin.
  • Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting.
  • Catecholaminergic control of intracellular free calcium and beta-endorphin secretion of rat pituitary intermediate lobe cells.
  • Effect of cooling on cutaneous microvascular adrenoceptors in vivo in the rabbit ear.
  • Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
  • Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration.
  • Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
  • In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia.
  • Improved high-performance liquid chromatographic analysis of terazosin in human plasma.
  • Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy.
  • Terazosin for vesicosphincter dyssynergia in spinal cord-injured male patients.
  • Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia.
  • Alpha-blocker therapy for benign prostatic hyperplasia: a comparative review.
  • Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues.
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
  • Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia.
  • Influence of new evidence on prescription patterns.
  • Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade.
  • Use of alpha1-adrenergic blockaders in voiding disorders in women







    DreamPharm: Herbal and Nutritional supplements online || Hair Million herbal formula for hair loss and hair growth || Wellstreet online pharmacy for click-order prescription medications || Altace Online Pharmacy || Rx Drugs USA, Prescription Drugs Online Pharmacy || Insurance plans and information || Insurance policies for all purposes || Antibiotics and prescription medications online literature ||